Page 171 - FINAL PROGRAM

Quality and safety of ART therapies
P-549 A comparison of dual triggering by administration of GnRH agonist plus HCG versus HCG in normal responders in ART outcomes
M. Farid Mojtahedi (Iran)
P-550 The long-term alterations of myocardial remodeling associated genes from birth to old age in assisted reproductive technology mice and mechanism involved
Q. Wang (China)
P-551 Neurodevelopmental and cardiometabolic outcome in 4-year-old twins and singletons born after in vitro fertilization
D. Kuiper (The Netherlands)
P-552 Factors affecting birthweight after single frozen-thawed embryo transfer
T. Habara (Japan)
P-553 ART laboratory disinfectants are not ‘embryosafe’ and should always be used with caution
S. Catt (Australia)
P-554 Comparison of birthweights in patients randomly assigned to fresh or frozen-thawed embryo transfer
B. Shapiro (U.S.A.)
P-555 Failure mode and effect analysis as a proactive method to prevent risks in Assisted Reproduction Technology (ART): a more than 1000 cycle-laboratory experience
G. Intra (Italy)
P-556 Fresh versus frozen-thawed embryo transfers: a systematic review and meta-analysis of obstetric outcomes
M. Roque (Brazil)
P-557 Is trial registration an indicator of risk of bias in fertility trials?
M. Showell (New Zealand)
P-558 Cumulative live birth rate following IVF and ICSI: a population-based cohort study
Z. Li (Australia)
P-559 Development of an external quality assessment (EQA) scheme for embryo morphology using the UK standard embryo grading scheme
J.D. Critchlow (United Kingdom)
P-560 Perinatal death after fertility treatment; a 7-year national cohort study in New Zealand on contributory factors and potential avoidability
S. Mourad (The Netherlands)
P-561 Assisted reproduction causes reduced fetal growth associated with downregulation of paternally expressed imprinted genes that enhance fetal growth
S. Chen (China)
FINAL PROGRAMME I HELSINKI, FINLAND – 3 TO 6 JULY 2016 167
POSTERS